Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age and older.

The chikungunya virus virus-like particle vaccine is well tolerated and shows high immunogenicity in both previous recipients ...

BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported financial ...

Valneva will work with local health authorities and wholesalers on the French island territory to distribute the vaccines.

Intech Investment Management LLC acquired a new stake in shares of HilleVax, Inc. (NASDAQ:HLVX – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with ...

The global animal vaccines market size was US$ 8.5 billion in 2021. The global animal vaccines market is forecast to grow to US$ 13.3 billion by 2030 by growing at a compound annual growth rate (CAGR) ...

December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults ...

A local Bucks County adult tested positive for measles after returning from a trip to Texas, health officials said.

“As the first virus-like particle single-dose, pre-filled syringe chikungunya vaccine, Vimkunya provides a crucial new tool to help protect at-risk individuals traveling to regions where the ...